Genetic influence on methadone treatment outcomes in patients undergoing methadone maintenance treatment for opioid addiction: A pilot study

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 1503-1508

  Samaan, Zainab ^a,b   Bawor, Monica ^a,b   Dennis, Brittany B ^a,b   Plater, Carolyn ^c   Varenbut, Michael ^c   Daiter, Jeffrey ^c   Worster, Andrew ^a,c   Marsh, David C ^c,d   Tan, Charlie ^e   Desai, Dipika ^b   Thabane, Lehana ^a,f,g   Pare, Guillaume ^g  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Ontario Addiction Treatment Centres   (Canada)

^d LAURENTIAN UNIVERSITY   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

Genetics; Risk factors; Substitute opioid therapy; Treatment response

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CANNABIS; CENTRAL STIMULANT AGENT; DIAMORPHINE; DNA; METHADONE; OXYCODONE; PERFORMANCE ENHANCING SUBSTANCE; PSYCHEDELIC AGENT;

ABCB1 GENE; ADULT; ARTICLE; BDNF GENE; BLOOD ANALYSIS; CES1 GENE; CES2 GENE; COHORT ANALYSIS; COMORBIDITY; CROSS-SECTIONAL STUDY; CYP2B6 GENE; CYP2D6 GENE; CYP3A4 GENE; DEMOGRAPHY; DRD2 GENE; DRUG USE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GENE; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPIATE ADDICTION; OPRD1 GENE; OPRM1 GENE; PILOT STUDY; PREVALENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS;

EID: 84907351773     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S66234     Document Type: Article

References (26)

1. World Health Organization. The World Health Report 2002. Reducing Risks, Promoting Healthy Life. Geneva: World Health Organization; 2002. Available from: http://www. who. int/whr/2002/en/whr02_en. pdf?ua=1. Accessed June 8, 2014.
2. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002; 360(9343): 1347-1360.
3. Zou S, Tepper M, Giulivi A. Current status of hepatitis C in Canada. Can J Public Health. 2000; 91 Suppl 1: S10-S15, S10-S16.
4. Wall R, Rehm J, Fischer B, et al. Social costs of untreated opioid dependence. J Urban Health. 2000; 77(4): 688-722.
5. Oppenheimer E, Tobutt C, Taylor C, Andrew T. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction. 1994; 89(10): 1299-1308.
6. Seal KH, Kral AH, Gee L, et al. Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay Area, 1998-1999. Am J Public Health. 2001; 91(11): 1842-1846.
7. Coutinho RA. HIV and hepatitis C among injecting drug users. BMJ. 1998; 317(7156): 424-425.
8. Brooner RK, King VL, Kidorf M, Schmidt CW Jr, Bigelow GE. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997; 54(1): 71-80.
9. Hall W, Bell J, Carless J. Crime and drug use among applicants for methadone maintenance. Drug Alcohol Depend. 1993; 31(2): 123-129.
10. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010; 363(21): 1981-1985.
11. Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2010 on CDC WONDER Online Database. 2012. Available from http://wonder. cdc. gov/mcdicd10. html. Accessed June 8, 2014.
12. Hamunen K, Laitinen-Parkkonen P, Paakkari P, et al. What do different databases tell about the use of opioids in seven European countries in 2002? Eur J Pain. 2008; 12(6): 705-715.
13. Mental Health and Addiction Information. Methadone. Toronto, ON: CAMH; 2010. Available from http://www. camh. ca/en/hospital/health_information/a_z_mental_health_and_addiction_information/methadone/Pages/methadone. aspx. Accessed June 30, 2014.
14. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009; 3: CD002209.
15. Jimenez-Treviño L, Saiz PA, García-Portilla MP, et al. A 25-year follow-up of patients admitted to methadone treatment for the first time: mortality and gender differences. Addict Behav. 2011; 36(12): 1184-1190.
16. Cousins G, Teljeur C, Motterlini N, McCowan C, Dimitrov BD, Fahey T. Risk of drug-related mortality during periods of transition in methadone maintenance treatment: a cohort study. J Subst Abuse Treat. 2011; 41(3): 252-260.
17. Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther. 2008; 12(2): 109-124.
18. Crettol S, Monnat M, Eap CB. Could pharmacogenetic data explain part of the interindividual sensitivity to methadone-induced respiratory depression? Crit Care. 2007; 11(1): 119.
19. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002; 41(14): 1153-1193.
20. Eap CB, Bertschy G, Baumann P, Finkbeiner T, Gastpar M, Scherbaum N. High interindividual variability of methadone enantiomer blood levels to dose ratios. Arch Gen Psychiatry. 1998; 55(1): 89-90.
21. Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Genet. 2005; 6(7): 521-532.
22. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005; 28(4): 321-329.
23. Dennis BB, Bawor M, Thabane L, Sohani Z, Samaan Z. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis. PLoS One. 2014; 9(1): e86114.
24. Marsden J, Gossop M, Stewart D, et al. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction. 1998; 93(12): 1857-1867.
25. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M. I. N. I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59 Suppl 20: S22-S33; quiz S34-S57.
26. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994; 23(2): 129-138.